Navidea Biopharmaceuticals Stock Fundamentals
NAVBDelisted Stock | USD 0.1 0.01 9.45% |
Navidea Biopharmaceuticals fundamentals help investors to digest information that contributes to Navidea Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Navidea Pink Sheet. The fundamental analysis module provides a way to measure Navidea Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Navidea Biopharmaceutica pink sheet.
Navidea |
Navidea Biopharmaceuticals Company Return On Equity Analysis
Navidea Biopharmaceutica's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Navidea Biopharmaceutica Return On Equity | -11.0 |
Most of Navidea Biopharmaceutica's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Navidea Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Navidea Biopharmaceuticals has a Return On Equity of -11.0012. This is 54.1% lower than that of the Biotechnology sector and 69.83% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Navidea Biopharmaceutica Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Navidea Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Navidea Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Navidea Biopharmaceutica competition to find correlations between indicators driving Navidea Biopharmaceutica's intrinsic value. More Info.Navidea Biopharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Navidea Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Navidea Biopharmaceutica's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Navidea Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Navidea Biopharmaceutica's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Navidea Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Navidea Biopharmaceutica by comparing valuation metrics of similar companies.Navidea Biopharmaceutica is currently under evaluation in return on equity category among its peers.
Navidea Fundamentals
Return On Equity | -11.0 | ||||
Return On Asset | -1.22 | ||||
Current Valuation | 3.5 M | ||||
Shares Outstanding | 100.08 M | ||||
Shares Owned By Insiders | 35.43 % | ||||
Shares Owned By Institutions | 1.50 % | ||||
Number Of Shares Shorted | 2.69 M | ||||
Price To Earning | 0.53 X | ||||
Price To Book | 8.16 X | ||||
Price To Sales | 84.14 X | ||||
Revenue | 65.65 K | ||||
Gross Profit | (119.3 K) | ||||
EBITDA | (14.05 M) | ||||
Net Income | (15.18 M) | ||||
Cash And Equivalents | 328.01 K | ||||
Cash Per Share | 0.01 X | ||||
Total Debt | 2.43 M | ||||
Debt To Equity | 1.20 % | ||||
Current Ratio | 0.22 X | ||||
Book Value Per Share | (0.01) X | ||||
Cash Flow From Operations | (8.99 M) | ||||
Short Ratio | 0.52 X | ||||
Earnings Per Share | (0.39) X | ||||
Target Price | 5.0 | ||||
Number Of Employees | 11 | ||||
Beta | 1.5 | ||||
Market Capitalization | 8.04 M | ||||
Total Asset | 4.37 M | ||||
Retained Earnings | (388 M) | ||||
Working Capital | (6.74 M) | ||||
Current Asset | 12.58 M | ||||
Current Liabilities | 6.18 M | ||||
Net Asset | 4.37 M |
About Navidea Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Navidea Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Navidea Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Navidea Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. Navidea Biopharmaceutica operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 11 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |